VJ, when you make a post like this is why you are called a pumper. You plainly stated;
"33 job listings filled since start of the year." Are you saying the jobs you date as 7/27/2015 were filled before 8AM this morning and you were notified that quick. Of course not. Those were FILED not all FILLED. Even when Fox asked you directly you avoided it and basically turned it into a teaser to join FB. If you make posts that you know are misleading how are you any different than the ones you battle with? It looks like your main goal now is to recruit YMB posters to FB and you will do anything to accomplish it, including deceit. Disappointed in you. Please take a moment and clarify your post.
I don't work in the medical or research field so it's hard for me to directly compare but from a laymans standpoint they look very much similar. If I remember alexp does work in these fields. If true it would have to cut at least a year off the time to market wouldn't you think?
"*they have advanced 3112 before their phase 1/2a trial reads out."
alexp, That statement is the most interesting. It does appear that is exactly what they have done. Have you ever seen this done before? By the time the P 1/2 trial results come out they will have already started the P2.
I can understand your concern irishmick. I'd be lying to say I have no concerns. I think by end of Sept it will all make more sense. I'm not saying the share price will skyrocket just that the science path will make more sense. We will see. GL
As someone who owns a business I can tell you the biggest reason is because you are looking to hire the best that is out there. The longer you take the more choices you have. The people you interview go back and tell co workers that you are looking for someone and sometimes you end up hiring the person who trained the original person you interviewed. As far as not hiring anyone, that just doesn't work with the math. Their headcount now is over 120. It has increased substantially every year. It will be higher this year than last. They started with 2. I have talked with IR about this and they were proud to say they have a very high retention rate. That is a direct result of being selective with new hires. GL
Why would you say 5 month? Did you not look it up? Are you just exaggerating to be lazy?
It has been 2 months so you are off about 150%.
18 Science related PR's in the last 18 months. Averaging about 1 science PR a month. How many do you think they should average a month?
There was a 4 month period of no science PR at the beginning of last year.
Peer review? This is from a peer reviewed paper. "Many journals, even in the age of the internet, take more than a year to review and publish a paper"
It's easy to just shoot from the lip but when you actually take a minute to look up the truth things are very different. This is the age where some people selfishly want things now. Like a small child does. Please post any facts you have otherwise just put "EXAG" in front of your post so everyone will know it is just an exaggeration out of frustration. GL
Yes we have Catch! I hope you watch the video i posted called Rapid Health Protection for the Population. He makes it clear that they are not disclosing a lot of info right now. I'm telling you Catch, I think this DARPA thing is the golden ticket. Look up Moderna and see what happened to them. They will IPO at some point and it will be huge. It all ties together with Wattendorf leading the way. I am all in at this point. As long as we have been here I don't ever remember the company being this quiet for this long. The little basher guy is absolutely frantic judging from all the ignored posts I see. The end will justify the means my friend.
Don't know if you saw it but the guy that won the boat at the Dauphin Island rodeo won it on his entry from a spec he caught out of a kayak. Made me think of you. GLTY
He tapped DNA vaccine specialists David Weiner at the University of Pennsylvania and David Ho at the Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University, for help with the DARPA program. Weiner has been working on the problem since the very beginning, and has seen the hype around DNA vaccines peak and then collapse when there were disappointing clinical trials. He’s written most of the scientific reviews of progress in the field and guest-edited a special edition of the journal Vaccine on DNA vaccines.
Google it for the story
COL Dan Wattendorf, Program Manager in DARPA’s Biological Technologies Office (BTO), discusses efforts to develop treatments against all infectious diseases
Any comments from some of the science/medical posters on here would be appreciated on how it may be related to Inovio. He mentions DNA and mabs numerous times.
Your opinion is obviously based on what will put a few dollars in your pocket the fastest and not about building a global pharma company. To build a large pharma company takes many years and a lot of money. when I first started buying shares in 2008 they had a EV of less than 40 mil. It is now over 500 mil. In the middle of that it is like watching grass grow. That's not Ino's fault, it is because of the complexity of what they are doing. I have seen so many posters come and go on here in that time frame. Most, like you, are looking to make fast money. I wish you luck but it just is not reality. Management simply don't care about what you think and rightly so. Do you realize how your opinion would go over in a room full of accomplished people like them? If you want to ride you have to grab a coat tail. You can always start your own company and do it any way you like.
These synthetic DNA vaccines induced robust humoral and polyfunctional CD4+ T-cell responses which fully protected animals against lethal challenge after just two immunizations. In addition, naïve animals administered immunized sera mixed with the lethal neurotoxin were 100% protected against intoxication. The data demonstrate the protective efficacy induced by a combinative synthetic DNA vaccine approach. This study has importance for the development of vaccines that provide protective immunity against C. botulinum neurotoxins and other toxins.
Thanks inoright. I see now where it has been posted before. Hard to keep up during the summer months.
NCT02431767 Phase 1
I can't find a PR on this but it is listed now on clinicaltrials website.
It's going to take a lot of hope for them (shorts) to succeed. The important part is not the ebola vaccine in it's self. They are using the grant to do preclinical on the dmabs. There is no real revenue stream in the ebola vaccine. There is a fortune to made if the dmabs are successful. You will see preclinical updates on the dmabs long before the vaccine IMO. I believe the dmabs are the biggest catalyst out there as far as revenue stream. It would be the game changer.